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We describe a patient with a three-year history of severe progressive left-sided glossopharyngeal neuralgia (GPN) that failed to
adequately respond to various drug therapies.The application of lidocaine spray to the posterior pharyngeal wall provided nomore
than short-term relief. Apart from a large hypertrophic tonsillectomy scar on the left side all clinical and radiologic findings were
normal. In terms of therapeutic local anaesthesia, the hypertrophic tonsillectomy scar tissue was completely infiltrated with the
local anaesthetic (LA) procaine 1%. The patient has been almost completely pain-free ever since, and the lidocaine spray is no
longer needed. Six weeks after the first treatment a repeat infiltration of the tonsillectomy scar led to the complete resolution of all
symptoms. The patient has become totally symptom-free without the need to take any medication now for two and a half years.
This is the first report of a successful therapeutic infiltration of a tonsillectomy scar using an LA in a patient with GPN that has
been refractory to medical treatment for several years. A possible explanation may be that the positive feedback loop maintaining
neurogenic inflammation is disrupted and “sympathetically maintained pain” resolved by LA infiltration.
1. Introduction
Glossopharyngeal neuralgia (GPN) is a facial pain syndrome
that is characterised by paroxysms of excruciating pain in
the sensory area innervated by the auricular and pharyngeal
branches of the glossopharyngeal nerve (ninth cranial nerve)
and the vagus nerve (tenth cranial nerve) [1]. Typically,
affected patients describe a unilateral shooting or lancinating
pain felt in the back of the throat in the tonsillar area that
can sometimes radiate to the ear. GPN is often missed or
misdiagnosed as trigeminal neuralgia (TN) [1].
Epidemiology. GPN is a rare condition; the estimated inci-
dence is reported to be in the range of 0.2 to 0.7 per 100,000
patients [2]. GPN is responsible for approximately 0.2 to
1.3% of all cases of facial pain syndromes [2] and has a peak
incidence in the fifth and sixth decades of life. GPN, other
than TN, affects both women and men equally [2, 3]. In most
patients, the pain occurs unilaterally with the left side being
more commonly affected than the right [1, 3], but bilateral
symptoms are observed in about 25% of the patients and are
thus muchmore common than in patients suffering from TN
[2].
Symptomatology. The clinical picture is characterised by
attacks of flash-like, shooting, stabbing, excruciating pain
that patients describe as electric shock- or knife- or pinprick-
like sensations. Somepatients can experience at the same time
dull persistent pain thatmay also feel like pressure or burning.
Usually, the pain is localised in the back part of the
tongue, the tonsils, the pharynx, the larynx, the middle ear,
and the angle of the mandible (gonial angle) [1].
Shooting pain can occur spontaneously but is usually
triggered by specific stimulating actions such as swallowing,
chewing, talking, laughing, yawning, sneezing, brushing
teeth or blowing the nose, or touching the ear and the back
of the neck. A cough may occur as both a trigger and an
accompanying symptom [3]. In some patients, the pain can
also be triggered by sweet, sour, cold, or hot food [1].
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Normally the pain attacks last from a few seconds to no
more than two minutes, the length of the intervals between
the attacks varying from several minutes to hours. The
frequency of attacks is variable, but the number of attacks
can amount to as many as several hundred a day. Pain attacks
usually take place during the daytime; however, theymay also
awaken patients at night.
During the pain attacks, about 10% of the patients
also experience severe vagal symptoms that may lead to
bradycardia, hypotension, syncope, seizures, or even cardiac
arrest [1, 3, 4], which can be explained by the specific fibre
composition in the glossopharyngeal nerve (see below).
Aetiology and Pathogenesis. The vast majority of GPN are
idiopathic; that is, they have no definable cause, and the
findings of the clinical examination of the head and the neck
are normal. Inmost cases, imaging studies (including CT and
MRI) will also yield results within normal limits.
Rarely, GPN can occur secondary to a definable cause;
the glossopharyngeal nerve may, for example, be compressed
by adjacent vascular structures, a tumour, an abscess, or
abnormal bony structures in the posterior cranial fossa or
in the nasopharyngeal space (parapharyngeal tumours or
abscesses, a calcified stylohyoid ligament, an elongated long
styloid process (so-called Eagle’s syndrome), in the context
of Paget’s disease) [1, 5]. Damage caused by inflammation,
for example, in patients with multiple sclerosis or Sjo¨gren’s
syndrome, has also been reported [1, 5]. Neuromas arising
from the ninth cranial nerve are rare and generally almost
asymptomatic [6].
Anatomy of the Glossopharyngeal Nerve. Developmentally,
the glossopharyngeal nerve (ninth cranial nerve) is the
nerve of the third pharyngeal (branchial) arch. It exits the
skull through the jugular foramen and courses behind the
stylopharyngeal muscle, moving distally. It receives sensory
fibres from the posterior one-third of the tongue, the pharyn-
geal mucosa, the tonsils, and the middle ear, and it supplies
motor fibres to, among others, the stylopharyngeal muscle,
which is responsible for elevating the soft palate during
speech and swallowing and is involved in producing the
pharyngeal reflex. In addition to sympathetic components,
the autonomic fibres of the glossopharyngeal nerve also
comprise afferent fibres from the carotid sinus baroreceptors
and the chemoreceptors in the carotid body (regulating
blood pressure and breathing) as well as parasympathetic
secretomotor fibres supplying the parotid gland.
Diagnosis and Differential Diagnosis. The diagnosis of GPN is
made based on thorough history-taking and a careful clinical
examination. The diagnostic criteria for classical GPN were
defined in 2013 by the International Headache Society and
have been summarised as follows (also see [7]).
Glossopharyngeal Neuralgia, Diagnostic Criteria (acc. to
Headache Classification Committee of the International
Headache Society (IHS), 2013 [7]).
(A) at least three attacks of unilateral pain fulfilling
criteria (B) and (C);
(B) pain is located in the posterior part of the tongue,
tonsillar fossa, or pharynx, beneath the angle of the
lower jaw, and/or in the ear;
(C) pain has at least three of the following four
characteristics:
(1) recurring in paroxysmal attacks lasting from a
few seconds to 2 minutes;
(2) severe intensity;
(3) shooting, stabbing, or sharp in quality;
(4) precipitated by swallowing, coughing, talking,
or yawning;
(D) no clinically evident neurological deficit;
(E) not better accounted for by another ICHD-3 diagno-
sis.
Anaesthesia of the posterior pharyngealwall, for example,
using lidocaine spray, followed by the temporary resolution of
symptoms is diagnostic of GPN [1, 8]. Imaging studies and,
as appropriate, liquor analysis are used to exclude or confirm
secondary GPN.
From the point of view of differential diagnosis, GPN
must, in particular, be distinguished from trigeminal neu-
ralgia, intermediate nerve neuralgia, and superior laryngeal
neuralgia.
Treatment Options. In analogy to the treatment of the
much more common trigeminal neuralgia, a therapeutic
trial with anticonvulsant drugs (carbamazepine, gabapentin,
oxcarbazepine, lamotrigine, or phenytoin) is recommended
in the first place; however, the evidence base for such an
approach is very poor, and, in particular, the conservative
long-term therapy has often proved to be difficult and
unsatisfactory [3, 5]. The usual painkillers are ineffective,
whereas antidepressants such as, for example, amitriptyline,
alone or in combination with an antiepileptic drug, can be
useful [1].
Invasive treatments,microvascular decompression, intra-
cranial partial rhizotomy, CT-guided radiofrequency ther-
mocoagulation, stereotactic tractotomy/nucleotomy of the
pars caudalis of the nucleus tractus spinalis nervi trigemini
with radiofrequency lesioning, and Gamma knife surgery,
can achieve successful results, especially in the immediate
postoperative period, but in many cases symptoms seem
to be recurring over time [9–11]. Furthermore, serious
complications may occur with invasive procedures [3].
Microvascular decompression seems to be associated with a
higher surgical risk in GPN than in TN patients [3].
In cases of inadequate response to medical treatment the
additional block of the glossopharyngeal nerve can lead to
substantial improvement, as different authors have described
in the past few years. Nerve blocking can be achieved using
nonneurolytic substances (LA alone and with adjuncts such
as steroids, ketamine, etc. [12–14]) or neurolytic substances
(phenol, alcohol, and glycerol [15]). The nerve is reached by
an intra- or extraoral access.
Various case reports from recent years have shown that in
refractory GPN treatment success can also be brought about
by “pulsed radiofrequency neurolysis” [16].
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2. Case Report
2.1. History and Findings. During his initial visit the 56-year-
old male patient reported that for three years he has been
increasingly suffering from a persistent dull, aching pain in
the left tonsillar region, which is nonradiating. The patient
is unaware of any precipitating event. In addition to this
progressive, persistent pain he is afflicted with episodes of
sharp, shooting pain that usually lasts from one to 15 minutes
and that is triggered by eating, drinking, talking, yawning,
and brushing teeth. Preauricular pressure also exacerbates
symptoms, which is why he can no longer sleep on his left
side. In addition, the pain is worsened by negative emotions
and stress.
Long-term treatment with lamotrigine, 2 × 50mg, and
oxcarbazepine, 2 × 375mg, provided inadequate pain relief,
and a pulse steroid therapy, which the patient received one
and a half years ago, had no effect whatsoever.
In an e-mail to his neurologist the desperate patient
summarised his situation as follows: “Now I muddle through
the day, with lidocaine spray, which I apply twice or thrice
hourly (every five minutes during meals, and about every
two hours at night). Within two minutes, the pain will then
disappear almost completely. This thing really takes it out of
me (mainly soft, and often tasteless, foods; weight loss; bad
moods, etc.).”
Otherwise, the patient is healthy, both physically and
emotionally, and, other than the above mentioned drugs, he
does not use any medication.
Apart from a tonsillectomy at the age of 9, the repair of a
left inguinal hernia, and a varicocele surgery some years ago
his medical history-taking revealed no other abnormalities.
The patient had previously been assessed by two neurolo-
gists and an ear, nose, and throat specialist; their examina-
tions showed no specific findings. The dental examination
(including an orthopantomography and an assessment of the
temporomandibular joints) did not show any abnormality
either. High-field (3 Tesla)MRI imaging of the neurocranium
yielded normal findings that did not detect a morphological
substrate and especially gave no indication of a mass lesion,
a vessel looping around the nerve, inflammatory changes in
the brain stem, vascular variants, or an aneurysm. Neither of
the two gonial angles showed signs of irritation.
The clinical examination revealed a large hypertrophic
posttonsillectomy scar (left more than right) that seemed to
exert traction on the mucosa.
2.2. Diagnosis. Idiopathic glossopharyngeal neuralgia on the
left side.
2.3. Treatment and Future Course. On his initial visit, the
patient’s hypertrophic tonsillectomy scar was directly infil-
trated with 1.5mL of the LA procaine 1% (without additives);
the infiltration was performed using a syringe (Uniject K)
with a very fine needle (0.3 × 23mm).
In less than aminute after infiltration the patient felt com-
pletely pain-free, and quite unlike the application of lidocaine
spray the procaine infiltration achieved permanent freedom
from pain (with respect to both the patient’s persistent pain
and the episodes of shooting pain).
Six weeks later, when the patient returned for his follow-
up visit, he reported that he was still virtually pain-free and
that he had reduced his medication dosage by 50%. Since the
infiltration of his tonsillectomy scar he had never used the
lidocaine spray again.
Subsequently, the infiltration was repeated as described
above; the patient continued to be pain-free, except for a week
when he experienced low-level painwhich did not require the
application of lidocaine spray, though.
After another six weeks the patient reported a “perfect
outcome.” Eating, teeth cleaning, talking, and so forth caused
him no pain any more. He had stopped taking any pain
medication, and treatment was no longer needed.The patient
has continued to be pain-free until the present day (two and
a half years).
2.4. Adverse Effects. No adverse effects were observed, except
a mild dizziness that appeared right after the injection and
lasted a few minutes.
3. Discussion
Based on the patient’s medical history we assumed that his
neuropathic pain was triggered by posttonsillectomy scar
tissue in response to irritation from traction (e.g., when
talking or swallowing) or pressure/touch (e.g., by food or by
lying on the affected side). Scars contain large amounts of
collagen. Collagen fibres behave similar to electrical dipoles.
In 1974, Athenstaedt demonstrated that electrical signals
can be registered upon any mechanical change in length or
any deformation of collagen fibres [17]. We think it may
be possible that action potentials are transmitted centrally
via nociceptive afferent fibres of the ninth cranial nerve
when the traction or the pressure exerted on collagen fibres
in scar tissue changes. Another possible source for action
potentials (ectopic generation) is neuromas in the scar tissue.
These mechanisms can lead, as in any chronic or repetitive
nociceptive stimulus, to peripheral (e.g., release of substance
P) and central sensitisation processes. Here, the autonomic
nervous system and, in particular, its sympathetic branch,
have a major role in maintaining positive feedback loops
[18, 19], which enhance these sensitisation processes [19].
An important factor in the development of these iterative
loops is the so-called sympathetic-afferent coupling [20–24].
In certain pathological conditions, sensory coupling may
occur between peripheral sympathetic efferent nerves and
afferent nociceptive neurons by producing a kind of short
circuit. Nociceptive afferents express adrenergic receptors
and can thus become susceptible to norepinephrine [20];
as a result the efferent sympathetic system gets connected
with the afferent nociceptive system as well: now, enhanced
sympathetic activity causes excitation of nociceptive afferents
thus generating the perception of pain. In terms of positive
feedback (iteration), additional minor (peripheral or central)
stimuli may be sufficient in this situation to evoke severe
pain [18]. This mechanism also offers an explanation of the
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increase in pain that our patient experienced for example, as
a result of negative emotions or stress.
Even nonirritated scars, which have been normal elec-
trophysiologically and asymptomatic for decades, can be
“activated” by sympathetic-efferent nerve fibres and thus
represent a permanent potential source of irritation [25].
Injections of LA have (although partially hypothetical)
a favourable effect on positive feedback mechanisms by
reducing the ectopic generation of action potentials [26] and
the peripheral sensitisation (e.g., release of substance P) [27],
by reducing or eliminating engramming in the sympathetic
nerve system [28], by reducing the activity of the sympatheti-
cally activated wide dynamic range (WDR) neurons [29] and
by disrupting neuronal reflex arcs. Subsequently they lead to
a new organisation (self-organisation) of the pain-processing
systems [18, 19].
Even in patients with chronic pain it is possible that
the effects of plastic changes with a central state of hyper-
excitability, which have been caused by irritation of or
damage to peripheral nerves, can be reversed by blocking
the spontaneous activity of sensitised nociceptive afferent
neurons with an LA [30]. Such a “desensitisation” or even
“extinction” of modulating or pain-enhancing signals is a
critical step in the management of pain [31].
The fact that procaine infiltration, as we have observed,
is helpful in generally softening even hard and hypertrophic
scars and thus subsequently attenuates the effects of the
traction and pressure mechanisms of collagen [17] may also
have contributed to reducing the irritation caused by the scar.
Due to the pathomechanisms that include the sympa-
thetic nerve system, another option might be considered,
namely, the therapeutic injection into the superior cervical
ganglion. This approach, however, was not required in the
case of the patient described because the peripheral “reset” at
the location of pain generation had led to complete freedom
from pain.
Finally, procaine has been reported to exhibit membrane-
stabilising, antiarrhythmic, muscle-relaxing, spasmolytic,
perfusion-enhancing, antihistaminic, anti-inflammatory,
sympatholytic, parasympatholytic, vasodilator, and DNA-
demethylating effects [27, 32, 33]. It contains a carboxylic
ester group, its duration of action is no more than
approximately 20 minutes and it is known for its limited
diffusibility. This is why procaine precisely exerts its effect at
the site of injection.
GPN can have a cyclical course with pain-free intervals.
This did not apply, though, in the case of our patient, who
had been suffering from progressive, chronic pain for three
years; also the superimposed stabbing pain was continuously
present. The current and lasting freedom from pain, which
our patient has experienced after procaine had been injected
into his tonsillectomy scar, can thus unambiguously be
attributed to the intervention and not to the fact that his GPN
followed a cyclical course.
We assume that this is the first description of a successful
treatment of refractory GPN by infiltration of a tonsillectomy
scar with an LA. Mascolo et al. were the only ones to publish
a similar case, however not a patient with infiltration of a
scar but of the soft palate [34]. They describe a male patient
with GPN that failed to respond to medical drug treatment
for several months. Prior to considering surgical therapy,
infiltration of bupivacaine 0.25% into the left side of the
soft palate and into the trigger points at the base of the
palatal arch was performed as a final attempt. Immediately
after the injection, the patient was totally pain-free, just
like our patient. Therapeutic local anaesthesia was repeated
when the pain reappeared 12 days after infiltration. After
the second treatment the pain disappeared completely. The
authors suggested that themost likelymechanism underlying
this treatment success was a disruption of the “sympathetic-
sensory coupling.”
4. Conclusion
If the standard diagnostic test for GPN, that is, the application
of lidocaine spray, is positive, we recommend the following.
(1) In tonsillectomised patients, inject an LA (procaine as
the drug of first choice) directly into the scar.
(2) In patients who still have their tonsils thoroughly
infiltrate the soft palate and the posterior pharyngeal
wall (in a depth of approximately 2mm, using a fine
needle), before surgical and/or interventional proce-
dures with uncertain therapeutic value and potential
complications are planned.
These injections are simple and, if performed lege artis, a
low-risk management of pain. Studies are required to explore
whether these findings can be generalised beyond the setting
described.
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